## **SUPPLEMENTARY MATERIAL:**

## Prognostic value of estimated plasma volume in patients with chronic systolic heart failure

Yuyao Lin, MD <sup>a, b</sup>, Yanbo Xue, MD <sup>a, b</sup>, Jing Liu, MD <sup>a, b</sup>, Xiqiang Wang, MD <sup>a, b</sup>, Linyan Wei, MD <sup>a, b</sup>, Jing Liu, MD <sup>a, b</sup>, Ling Bai, MD <sup>a, b, \*</sup>, Aiqun Ma, MD, PhD <sup>a, b, c, \*</sup>

<sup>a</sup> Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, People's Republic of China

<sup>b</sup> Key Laboratory of Molecular Cardiology; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, No. 277 West Yanta Road, Xi'an, Shaanxi, China <sup>c</sup> Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University),

Ministry of Education, People's Republic of China

## \*Corresponding author:

Aigun Ma, MD, PhD, and Ling Bai, MD,

Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, No. 277 West Yanta Road, Xi'an, 710061, Shaanxi Province, the People's Republic of China

Telephone: +86-13709117138 and +86-13759958590.

E-mail: aiqun.ma@xjtu.edu.cn; maaiqun1108@126.com and bailingb21@sina.com.

**Table S1**Characteristics of the study population

35.6 months follow-up	All Patients	First	Second	Third	P Value
	N = 231	$ePVS \le 3.56$	<b>[3.56 &lt; e PVS</b>	(ePVS >	
		dl/g (n = 77)	≤ <b>4.3</b> 5 dl/g ]	4.35dl/g]	
			(n = 77)	(n = 77)	
Primary outcome	59.7%, n = 138	48.1%, n = 37	59.7%, n = 46	71.4%, n = 55	0.013
All cause death	26.0%, n = 60	14.3%, n = 11	28.6%, n = 22	35.1%, n = 27	0.011
Re-hospitalization	52.8%, n = 122	41.6%, n = 32	49.4%, n = 38	67.5%, n = 52	0.004

Abbreviations as in Table 1

 $\label{eq:correlation} \textbf{Table S2}$  Correlation and collinearity between ePVS, logBNP and LVEF

	logBNP	ePVS	LVEF, %
logBNP	-	-	-
ePVS	Pearson Correlation: 0.298	-	-
	P < 0.001		
LVEF, %	Pearson Correlation: -0.229	Pearson Correlation: -0.008	-
	P < 0.001	P = 0.903	
LVEF ≤ 40%	Pearson Correlation: -0.149	Pearson Correlation: -0.097	-
	P = 0.063	P = 0.230	
40% < LVEF < 50%	Pearson Correlation: -0.034	Pearson Correlation: 0.250	-
	P = 0.771	P = 0.031	

Abbreviations as in Table 1

Table S3

Association between baseline variables and primary outcome in Univariable Cox regression analysis

Variables	Univariable HR (95% Cl)	P Value
Age, years	1.012 (0.993-1.031)	0.209
Male, n	0.711 (0.509-0.995)	0.047
BMI, kg/m <sup>2</sup>	0.981 (0.940-1.023)	0.371
Hypertension, n	1.037 (0.720-1.495)	0.844
Diabetes, n	0.864 (0.477-1.564)	0.628
Coronary artery disease, n	1.301 (0.911-1.858)	0.148
NYHA I/II/III/IV, %		0.006
NYHA I	0.354 (0.192-0.651)	0.001
NYHA II	0.927 (0.634-1.353)	0.693
logBNP	2.427 (1.639-3.593)	< 0.001
MAGGIC score	1.056 (1.023-1.089)	0.001
LVEF, %	0.958 (0.938-0.979)	< 0.001
Systolic BP, mmHg	0.992 (0.984-1.001)	0.079
Albumin, g/dl	1.005 (0.958-1.055)	0.830
BUN, mg/dl	0.976 (0.890-1.070)	0.604
Sodium, mmol/l	0.993 (0.934-1.055)	0.993
Uric acid, mg/dl	1.001 (0.999-1.002)	0.591
Hemoglobin, g/dl	0.978 (0.969-0.988)	< 0.001
Hematocrit, %	0.936 (0.907-0.965)	< 0.001
ePVS	1.659 (1.358-2.027)	< 0.001
eGFR, ml/min per 1.73 m <sup>2</sup>	0.993 (0.985-1.002)	0.111
ACEI/ARB, %	0.907 (0.592-1.391)	0.655
Beta blocker, %	1.200 (0.767-1.878)	0.425

Aldosterone antagonist, %	1.289 (0.858-1.938)	0.221
Diuretics, %	0.737 (0.523-1.038)	0.081
Digitalis, %	1.213 (0.817-1.802)	0.338

Abbreviations: HR = Hazard Ratio; CI = confidence interval; other abbreviations as in Table 1

**Table S4**Subgroups analyses: univariable cox regression analysis for primary outcome.

Subgroups		univariable cox regression analysis for primary outcome	
	-	HR ratio (95%Cl) for ePVS	P Value
LVEF	LVEF ≤ 40% (n=156, 112 events)	1.547 (1.234 – 1.940)	< 0.001
	40% < LVEF < 50% (n=75, 26 events)	2.389 (1.510 – 3.779)	< 0.001

Abbreviations: HR = Hazard Ratio; CI = confidence interval; other abbreviations as in Table 1

Table S5

Model	HR ratio (95%Cl) for ePVS	P Value	
ePVS	1.646 (1.342-2.019)	< 0.001	
ePVS + age + gender	1.646 (1.342-2.019)	< 0.001	
ePVS + MAGGIC score + logBNP	1.635 (1.326-2.017)	< 0.001	
ePVS	1.644 (1.297-2.084)	< 0.001	
ePVS + age + gender	1.742 (1.331-2.280)	< 0.001	
ePVS + MAGGIC score + logBNP	1.584 (1.241-2.022)	< 0.001	
	ePVS  ePVS + age + gender  ePVS + MAGGIC score + logBNP  ePVS  ePVS  ePVS + age + gender	ePVS 1.646 (1.342-2.019)  ePVS + age + gender 1.646 (1.342-2.019)  ePVS + MAGGIC score + logBNP 1.635 (1.326-2.017)  ePVS 1.644 (1.297-2.084)  ePVS + age + gender 1.742 (1.331-2.280)	ePVS 1.646 (1.342-2.019) < 0.001  ePVS + age + gender 1.646 (1.342-2.019) < 0.001  ePVS + MAGGIC score + logBNP 1.635 (1.326-2.017) < 0.001  ePVS 1.644 (1.297-2.084) < 0.001  ePVS + age + gender 1.742 (1.331-2.280) < 0.001

Competing risk regression analysis for HF re-hospitalization.

Abbreviations: HR = Hazard Ratio; CI = confidence interval; other abbreviations as in Table 1

Table S6

Term	P Value
ePVS	0.009
anemia	0.265
ePVS * anemia	0.275

Test for interaction between ePVS and anemia on primary outcome.

Abbreviations: abbreviations as in Table 1